Immune Effects of Bevacizumab: Killing Two Birds with One Stone
作者： Yasir Y. Elamin , Shereen Rafee , Sinead Toomey , Bryan T. Hennessy
DOI: 10.1007/S12307-014-0160-8
关键词:
摘要: Angiogenesis or new vessel formation is essential for tumour growth and progression. Therefore, targeting angiogenesis has been an attractive strategy in the treatment ofcancer. Bevacizumab a recombinant humanized monoclonal IgG1 antibody thattargets vascular endothelial factor-A (VEGF-A) - key molecular player inangiogenesis. Bevacizumumab shown clinical efficacy phase III trials inseveral advanced solid malignancies. The of bevacizumumab isprimarily due to its antiangiogenic effects; however, there are direct antitumor effectsand immunomodulatory effects. Enhancing immune system restore itsantitumour activity utilized successfully setting. In this article we willdiscuss possible effects most clinically usedantiangiogenic agent; bevacizumumab.
springer.com
sci-hub.se 参考文章(64)
Robert J. Melder, Gerald C. Koenig, Brian P. Witwer, Nina Safabakhsh, Lance L. Munn, Rakesh K. Jain, During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Medicine. ,vol. 2, pp. 992- 997 ,(1996) , 10.1038/NM0996-992
M. Rita I. Young, Kristin Kolesiak, Mark A. Wright, Dmitry I. Gabrilovich, Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor Clinical & Experimental Metastasis. ,vol. 17, pp. 881- ,(1999) , 10.1023/A:1006708607666
Barbara Ensoli, Joseph A. Sonnabend, Rita Gendelman, Phillip D. Markham, Robert C. Gallo, Yoshiki Watanabe, Vivien Kao, Felipe Samaniego, Kimberly Kowalski, Aldo Pintus, Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. American Journal of Pathology. ,vol. 152, pp. 1433- 1443 ,(1998)
B Barleon, S Sozzani, D Zhou, HA Weich, A Mantovani, D Marme, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood. ,vol. 87, pp. 3336- 3343 ,(1996) , 10.1182/BLOOD.V87.8.3336.BLOODJOURNAL8783336
N G Gavalas, M Tsiatas, O Tsitsilonis, E Politi, K Ioannou, A C Ziogas, A Rodolakis, G Vlahos, N Thomakos, D Haidopoulos, E Terpos, A Antsaklis, M A Dimopoulos, A Bamias, VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 British Journal of Cancer. ,vol. 107, pp. 1869- 1875 ,(2012) , 10.1038/BJC.2012.468
Tae-Hee Lee, Hava Avraham, Seung-Hoon Lee, Shalom Avraham, Vascular Endothelial Growth Factor Modulates Neutrophil Transendothelial Migration via Up-regulation of Interleukin-8 in Human Brain Microvascular Endothelial Cells Journal of Biological Chemistry. ,vol. 277, pp. 10445- 10451 ,(2002) , 10.1074/JBC.M107348200
Bernard Escudier, Cezary Szczylik, Camillo Porta, Martin Gore, Treatment selection in metastatic renal cell carcinoma: expert consensus Nature Reviews Clinical Oncology. ,vol. 9, pp. 327- 337 ,(2012) , 10.1038/NRCLINONC.2012.59
M. Moniz, J. Yeatermeyer, T.-C. Wu, Control of cancers by combining antiangiogenesis and cancer immunotherapy. Drugs of Today. ,vol. 41, pp. 471- 494 ,(2005) , 10.1358/DOT.2005.41.7.893623
Bruce I. Terman, Maureen Dougher-Vermazen, Miguel E. Carrion, Dragan Dimitrov, Douglas C. Armellino, Denis Gospodarowicz, Peter Böhlen, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochemical and Biophysical Research Communications. ,vol. 187, pp. 1579- 1586 ,(1992) , 10.1016/0006-291X(92)90483-2
Gregory T Motz, Stephen P Santoro, Li-Ping Wang, Tom Garrabrant, Ricardo R Lastra, Ian S Hagemann, Priti Lal, Michael D Feldman, Fabian Benencia, George Coukos, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature Medicine. ,vol. 20, pp. 607- 615 ,(2014) , 10.1038/NM.3541